Click on a filter below to refine your search. Remove a filter to broaden your search.
A reduced risk for Alzheimer’s disease, vascular dementia and Parkinson’s disease was seen with SGLT2i use in type 2 diabetes.
The association was strongest among men and people with poor cardiometabolic health.
The findings show a greater effect with longer treatment, compared with dipeptidyl peptidase-4 inhibitors.
Nighttime light exposure was more strongly linked to AD prevalence than any other disease factor among those younger than 65 years.
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.